文献速递系统性红斑狼疮其他结缔组织病

系统性红斑狼疮症状聚类分析的预后洞察

Prognostic insights from symptom clustering analysis in systemic lupus erythematosus.
PubMed 文献 · RMD Open · 2025-04-09

这项回顾性研究纳入278例符合2019年EULAR/美国风湿病学会分类标准的SLE患者,基于23项临床表现分别在诊断时和末次随访时进行层次聚类分析,识别出三个症状簇。簇2/2'表型最重,肾脏受累62.2%(p<0.0001)、抗DNA抗体阳性90.0%(p=0.0151)、抗Sm抗体阳性34.4%(p<0.0001),预后较差;簇3/3'中50.0%符合MCTD定义(p<0.0001),抗U1-RNP 70 kDa抗体阳性87.5%(p<0.0001)。

要点

  • 诊断时和末次随访时均识别出三个症状簇,临床特征一致。
  • 簇1/1'以早期关节(95.3%,p=0.0043)和黏膜皮肤(58.7%,p=0.0031)症状为主,生存率最佳。
  • 簇2/2'表型最重,肾脏受累62.2%、抗DNA抗体阳性90.0%、抗Sm抗体阳性34.4%,预后较差。

核心结论

  • 在SLE患者中识别出明确的MCTD表型、预后较差的严重SLE表型以及内脏受累较低的第三组患者。
  • 症状簇随时间保持稳定,为疾病进展提供了洞察。

研究设计与样本

  • 回顾性研究,纳入278例符合2019年EULAR/美国风湿病学会分类标准的SLE患者。
  • 从患者病历中提取人口学、临床和免疫学特征数据。
  • 基于23项临床表现,分别在诊断时和末次随访时进行两次层次聚类分析。
  • 评估自身抗体在各簇中的分布,并采用Cox回归模型进行生存分析比较预后。

主要发现

  • 诊断时识别出三个症状簇,并在末次随访时得到确认,临床特征一致。
  • 最大的簇1/1'表现为早期关节症状(95.3%;p=0.0043)和黏膜皮肤症状(58.7%;p=0.0031),生存率最佳。
  • 簇2/2'表型最重,包括肾脏受累(62.2%;p<0.0001)、抗DNA抗体阳性(90.0%;p=0.0151)和抗Sm抗体阳性(34.4%;p<0.0001),预后较差。
  • 簇3/3'中符合MCTD定义的SLE患者比例高(50.0%;p<0.0001),抗U1-RNP 70 kDa抗体阳性率为87.5%(p<0.0001)。
  • 簇1和簇2随访期间保持稳定,簇2甚至随时间扩大,而簇3超过半数患者转入不同亚组。

关键数值与推荐

  • 簇1/1':关节症状95.3%(p=0.0043),黏膜皮肤症状58.7%(p=0.0031)。
  • 簇2/2':肾脏受累62.2%(p<0.0001),抗DNA抗体阳性90.0%(p=0.0151),抗Sm抗体阳性34.4%(p<0.0001)。
  • 簇3/3':符合MCTD定义50.0%(p<0.0001),抗U1-RNP 70 kDa抗体阳性87.5%(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE), a systemic autoimmune disease with heterogeneous severity, poses a challenge in classifying patients due to its dynamic phenotype. We therefore aimed to identify clinical clusters at diagnosis and at the last available visit to define subgroups with different disease trajectories. METHODS: This retrospective study included 278 SLE patients fulfilling the 2019 EULAR/American College of Rheumatology classification criteria. Data were extracted from the patient's medical record, encompassing demographic, clinical and immunological features. Two hierarchical clustering analyses were performed: one at diagnosis and the other at the last available visit based on 23 clinical manifestations. We assessed the distribution of autoantibodies among clusters, and survival analyses compared prognosis using the Cox regression model. RESULTS: Three symptom clusters were identified at diagnosis and confirmed at the last available visit, with consistent clinical profiles. The largest, clusters 1/1', exhibited early articular (95.3%; p=0.0043) and mucocutaneous (58.7%; p=0.0031) symptoms with the best survival rate. Clusters 2/2' displayed the most severe phenotype, including renal involvement (62.2%; p<0.0001), positivity for anti-DNA (90.0%; p=0.0151) and anti-Sm (34.4%; p<0.0001) autoantibodies, and worse prognosis. Clusters 3/3' exhibited a high proportion of SLE patients fulfilling the definition of mixed connective tissue disease (MCTD) (50.0%; p<0.0001) with anti-U1-RNP 70 kDa autoantibodies (87.5%; p<0.0001). Clusters 1 and 2 remained stable during follow-up, cluster 2 even expanding over time, while over half of cluster 3 patients transitioned to a different subgroup. CONCLUSION: We identified a distinct MCTD phenotype within SLE patients, a severe SLE phenotype with poor prognosis, and a third group of SLE patients with lower visceral involvement. Clusters remained stable over time, providing insights into disease progression.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Le Tallec E, Bourg C, Bouzillé G, et al. Prognostic insights from symptom clustering analysis in systemic lupus erythematosus. RMD Open. 2025. PMID: 40210260. doi:10.1136/rmdopen-2024-005330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。